RxDoctor Payments Data

James Makemson, MD

Family Medicine · Huntsville, ALNPI 1942283122

Payments from drug & device makers

$12,649in general payments, 2019–2025

Across 759 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • AstraZeneca$994
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$542
  • Takeda Pharmaceuticals U.S.A., Inc.$415
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,52099%
  • Education$1291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)125$2,283
Novo Nordisk140$1,640
Lilly USA, LLC65$1,167
AstraZeneca55$994
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$542
Takeda Pharmaceuticals U.S.A., Inc.27$415
Astellas Pharma US Inc18$392
Pfizer20$359
GSK18$284
Axsome Therapeutics, Inc.16$273
Boehringer Ingelheim15$246
Eisai Inc.18$225
Abbott11$218
Biohaven Pharmaceutical Holding Company Ltd.8$217
Otsuka America Pharmaceutical, Inc.10$217
Merck14$206
Supernus Pharmaceuticals, Inc.11$200
IBSA Pharma Inc.5$199
Amgen11$190
Johnson & Johnson9$156
Kowa Pharmaceuticals America, Inc.10$152
Corium, LLC7$145
Vanda Pharmaceuticals Inc.8$140
Exact Sciences7$136
Adlon Therapeutics L.p.7$110
Currax Pharmaceuticals LLC7$107
Lundbeck LLC5$101
Amarin Pharma, Inc.7$101
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$92
Bayer5$87
Bausch Health US, LLC5$83
Tris Pharma Inc5$77
Harmony Biosciences LLC2$61
Sanofi Pasteur Inc.3$59
Tolmar, Inc.3$56
Idorsia Pharmaceuticals US Inc3$48
Neos Therapeutics, LP3$48
Corcept Therapeutics2$47
Genentech USA, Inc.3$43
Daiichi Sankyo Inc.2$41
Sumitomo Pharma America, Inc.2$36
Novartis2$35
Vivus LLC2$34
Nalpropion Pharmaceuticals LLC2$32
E.r. Squibb & Sons, L.L.C.2$31
Phathom Pharmaceuticals, Inc.2$29
AMAG Pharmaceuticals, Inc.2$26
Teva Pharmaceuticals USA, Inc.2$25
Noven Therapeutics, LLC1$25
Jazz Pharmaceuticals Inc.1$22
Dexcom, Inc.1$21
Paratek Pharmaceuticals, Inc.1$20
Ironwood Pharmaceuticals, Inc1$19
Almatica Pharma LLC1$19
Acella Pharmaceuticals, LLC1$18
Biohaven Pharmaceuticals, Inc.1$18
Aytu Biopharma, Inc.1$16
Amryt Pharma Holdings Ltd1$16
Antares Pharma, Inc.1$14
Upsher-smith Laboratories LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,649 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$68,085
Medicare patients
250
Services billed
1,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide33$62,525
MounjaroTirzepatide45$47,995
JardianceEmpagliflozin41$44,240
RybelsusSemaglutide12$26,123
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$19,045
OzempicSemaglutide12$17,615
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,966
SavellaMilnacipran Hcl11$4,903
Omeprazole253$4,865
Levothyroxine Sodium326$4,652
Incruse ElliptaUmeclidinium Bromide12$4,182
SynthroidLevothyroxine Sodium54$3,525
Atorvastatin Calcium235$3,187
Irbesartan72$3,048
Valsartan72$2,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,167$110,52178 claims
Boehringer IngelheimJardiance, Stiolto Respimat$246$50,20552 claims
Novo NordiskRybelsus, Ozempic$1,640$43,73824 claims
GSKTrelegy Ellipta, Incruse Ellipta$284$23,22837 claims
AbbVieSavella, Synthroid$2,283$8,42865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →